Building A Culture Of Innovation

Investing In Our People

The DNA of o2h is centred around the nurturing of its people, values and culture, it reflects in the way we work with each other, as well as our collaborators and partners. Our set of values are centred around the speed at which we learn, innovation, teamwork, attention to detail, energy, delivery, integrity, and community..

Culture

career

The DNA of o2h is centred around the nurturing of its people, values and culture, it reflects in the way we work with each other, as well as our collaborators and partners. 

Our set of values are centred around the speed at which we learn, innovation, teamwork, attention to detail, energy, delivery, integrity, and community.

Values

value

The values that have historically permeated o2h in relation to discovery services are essential to the confidence and quality of the relationship o2h has with its clients. 

We value integrity in communication and action; social responsibility with respect to waste management and making a contribution to the community; and we possess an energetic can-do attitude. As a company we understand that in order to maintain the loyalty of clients we need to work closely as a team, show attention to detail and deliver. o2h continuously looks for improvements in every aspect of its activity and performance.

o2h understands that the best companies in the world invest genuine time and effort in the career development, performance management, feedback mechanisms and training of its teams. o2h has developed a career plan for all its scientists which ensures that the scientists are set new challenges at every stage of their career and are provided the necessary training in order to reach the next level of performance.

Team building

team-building

We have developed an active social program that has included bowling, restaurants, community work, cinema, restaurants and of course our o2h cricket team which ensures there is more to working in o2h than just chemistry/biology!

The team are constructively engaged in operational activity of the company and are encouraged to participate in discussions and decision making which impacts the issues that affect performance of the business.

Operational task list
All scientists in o2h are responsible for different areas of operational effectiveness. This ensures that o2h scientists take more pride, ownership and involvement in the running of ‘their’ lab (e.g. roles are assigned such as “Energy Saving Manager” in which the most recent electricity bill is sent to the whole team along with suggestions for saving energy). He or she is asked to report back to the operations task list coordinator on a weekly basis and the notes are distributed to the whole team.

Team meeting minutes
All o2h communications, issues, house-keeping, safety, training, equipment, team and lab related issues are discussed with the entire team from 9-9.45am every Wednesday morning. Minutes and actions are then circulated throughout o2h within 24 hours.

News

22 Jun 2018

PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has entered into a collaboration with o2h discovery (o2h), an Anglo-Indian medicinal chemistry company that has in-house capability to take drug discovery programmes to the IND filing stage. PhoreMost has built a pipeline of novel targets and early drug discovery programmes using its next-generation “SITESEEKER®” phenotypic screening platform. The collaboration will see o2h deploy its expertise in medicinal chemistry to help progress PhoreMost’s portfolio rapidly through the hit-to-lead and lead-optimisation stages of drug discovery. Dr Chris Torrance CEO of PhoreMost, said: “Since its inception, PhoreMost’s model has been to forge a new approach to drug discovery, working collaboratively with partners in order to progress new medicines. The alliance with o2h truly reflects this, and represents an important step in our mission to bring a greater diversity of therapies to patients, more quickly and at affordable prices.”  We have been impressed by the ability of PhoreMost’s SITESEEKER platform to systematically identify first-in-class drug targets in areas of high unmet need, and are excited to be applying our highly complementary capabilities to develop these potentially high value programs,” said Sunil Shah, CEO of o2h discovery: “Our shared vision of working collaboratively is also a testament to the strength of the Cambridge UK Biotech cluster for discovery and progressing the next generation of therapeutics.” PhoreMost recently announced the completion of an £11m ($15m) Series-A investment round. The investment will be used to expand operations on the Babraham Research Campus and progress several novel drug targets from its next-generation “SITESEEKER” phenotypic screening platform into first-in-class drug discovery programmes. Press Link - Phoremost and o2h Discovery

18 Apr 2018

Curza Global, LLC and O2H DISCOVERY (O2H) are pleased to announce a multi FTE chemistry collaboration to support Curza as it drives its lead program targeting dram negative through lead optimization and towards the clinic. Curza’s lead program is a new class of broad spectrum antibiotics, focused on ESKAPE pathogens and drug-resistant Gram-negative bacteria. Inspired by a natural product, this class targets an unexploited binding site of the bacterial ribosome. o2h is pleased to collaborate with industry leader, Curza, to tackle the rapid and global spread of antimicrobial resistance. Working through different pathways Curza hopes to design effective new drugs to tackle gram-negative infections The approach Curza has taken is unique and management is very focused to ensure their drug makes its way to patients quickly. Sunil Shah, CEO of O2h “The rapid and global spread of antimicrobial-resistant organisms in recent years has been unprecedented. Although resistant Gram-positive infections have been concerning to clinicians, the increasing incidence of antibiotic-resistant Gram-negative infections have become the most pressing issue in bacterial resistance.” Ryan Davies, CEO of Curza “We are very happy to be working with O2h on this program. We wanted to make fast progress with this project and O2h’s focus on execution speed is a key reason why we selected them to work on our highest priority project. About O2h: o2h seeds new ideas in science, technology and social enterprise. We work across boundaries and take a collaborative and shared approach to innovation, and therefore we co-invest, co-create and co-execute to bring these ideas to life. o2h discovery is an integrated chemistry and biology services capability for collaborative research and o2h ventures supports early stage life science assets through seed investment. o2h is organized into 6 verticals including discovery, ventures, technology, therapeutics, co-work and community, and is co-located in Ahmedabad, India and in Cambridge UK. Please see www.o2h.com for more details. About Curza: Curza is a Utah-based drug development company focused on developing novel therapeutics to control antibiotic resistant bacteria. With original technology licensed from the University of Utah, Curza is in the early stages of developing two novel classes of antibiotics. Headquartered in Salt Lake City, UT with offices in Cambridge, MA, Curza is privately held and backed by Clarke Capital Partners and other private investors. Please visit www.curza.com for more information.

02 Nov 2017

The quest to positively benefit the lives of patients in the world of drug discovery means finding novel therapeutics for unmet medical needs. The biotech and pharma companies have been increasingly resorting to external innovation to supplement their pipeline of ideas and turbocharge their research-based businesses with enterprising partners with complementary ideas, capabilities and services. It is therefore hardly surprising that the top medicinal chemists working in both large and small companies have multiple partners across different continents and time-zones. To deliver these iterative discovery projects often entails detailed co-ordination of inter-related activities and extensive multi-tasking. Project management is the hub that allows these complex matrices of networks to communicate and for the project to successfully advance. In today’s fast paced and technologically advanced digital world, providing the project manager the right tools to make informed decisions is key to successful delivery. o2h Discovery’s innovative app Chemistry in the Cloud TM builds upon the latest advances in secure cloud-based mobile technology and integrates project management of external drug discovery programs. The app enables communication between the various scientific stakeholders essential to successful project advancement leading to faster decision making. It negates the onerous tasks of weeding out critical information that is required to take a complex decision by extracting the information from large data intensive reports and databases. These crucial decision points are now just a ‘tap/swipe-of-the-finger’ in the Chemistry in the CloudTM app so that they can speedily execute tasks anytime, anywhere. The communication covering a gamut of research activities in relation to process of research now truly happens in 24/7 real-time. o2h announced a worldwide launch and first live demonstration of our revolutionary project management app – Chemistry in the Cloud TM on 10th September 2017 at the 19th RSC/SCI Cambridge medicinal chemistry conference to some of world’s top scientists. The app’s full suite of project management tools is available exclusively to live project collaborators and a lighter version is open for researchers looking for a quote for the synthesis of small molecules. https://www.linkedin.com/in/sunil-shah-4bb225/detail/recent-activity/shares/ Nilesh Dagia (nilesh@o2h.com) is the COO @ o2h Discovery

@o2hventures

November 1st 2017 10:11:52

O2h Discovery: Chemistry in the Cloud™ - The World's First App To Project Manage Drug Discovery - https://t.co/LP0dpstmFI

@o2hventures

November 13th 2017 12:11:27

Read our COO Nilesh Dagia's thoughts on our App Launch - "CHEMISTRY IN THE CLOUD TM – The World’s First APP to Pro… https://t.co/kQpz3s74Om

Woman in science and tech

Register interest in our 2018/2019 o2h Ventures EIS Therapeutics Fund